Regenxbio's Wet AMD Data Is Encouraging, With Majority Of Patients Free Of Rescue Injections [Seeking Alpha]
REGENXBIO Inc. (RGNX)
Last regenxbio inc. earnings: 2/26 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.regenxbio.com
Company Research
Source: Seeking Alpha
Regenxbio's Wet AMD Data Is Encouraging, With Majority Of Patients Free Of Rescue Injections Summary Regenxbio announced that it had achieved positive interim results from its phase I/IIa study using RGX-314 to treat patients with wet age-related macular degeneration. Besides proving its NAV nology Platform with RGX-314 in wet age-related macular degeneration, it had licensed its NAV AAV9 gene therapy tech for Zolgensma. Regenxbio has a proven model for its gene therapy as it has 20+ companies that have licensed its NAV nology Platform for use with expected milestone payments/royalties stemming from them. RGX-314 as a gene therapy, being used to treat patients with wet age-related macular degeneration, sets out to reduce the amount of injections required throughout the year for patients to maintain vision. REGENXBIO Inc. (Regenxbio) ( RGNX positive results ADVM NVS Initial Data Is Strong With A Single Cohort Showing Longevity The phase I/IIa open-label study is using RGX-314 to treat
Show less
Read more
Impact Snapshot
Event Time:
RGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RGNX alerts
High impacting REGENXBIO Inc. news events
Weekly update
A roundup of the hottest topics
RGNX
News
- REGENXBIO Inc. (NASDAQ: RGNX) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $35.00 price target on the stock.MarketBeat
- REGENXBIO Inc. (NASDAQ: RGNX) had its price target lowered by analysts at HC Wainwright from $40.00 to $36.00. They now have a "buy" rating on the stock.MarketBeat
- REGENXBIO Inc. (NASDAQ: RGNX) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $52.00 price target on the stock.MarketBeat
- REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA [Yahoo! Finance]Yahoo! Finance
- REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATAPR Newswire
RGNX
Earnings
- 11/6/24 - Miss
RGNX
Sec Filings
- 12/9/24 - Form 424B5
- 12/9/24 - Form 8-K
- 11/14/24 - Form SC
- RGNX's page on the SEC website